Mepsevii

Vestronidase alfa, the active ingredient in Mepsevii, is an enzyme replacement therapy presented as an injectable solution for intravenous use. It treats mucopolysaccharidosis type VII (Sly syndrome) in patients with the inherited lysosomal enzyme deficiency.

GNH USA supplies Mepsevii as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Mepsevii is used to address the lysosomal storage disorder pathway in mucopolysaccharidosis type VII.

- Mucopolysaccharidosis type VII (Sly syndrome): Improves degradation of accumulated glycosaminoglycans, reducing organ enlargement and disease progression. - Skeletal involvement in MPS VII: Helps lessen bone disease and joint stiffness associated with the condition. - Respiratory complications in MPS VII: Supports better pulmonary function by decreasing airway obstruction caused by substrate accumulation.

Mepsevii may be associated with a range of adverse reactions observed during clinical use.

Common Side Effects: - Infusion‑related reactions (e.g., chills, flushing, or rash) - Fever or elevated body temperature - Headache - Nausea or vomiting

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reactions - Significant elevation of liver enzymes (ALT, AST) - Thrombocytopenia or other hematologic abnormalities

Prior to initiating therapy with Mepsevii, several precautions should be considered to ensure patient safety.

- Monitor liver function tests: assess ALT and AST levels before and during treatment. - Assess for hypersensitivity: discontinue if severe allergic reactions occur. - Evaluate cardiac status: patients with pre‑existing heart disease should be closely observed. - Review renal function: dose adjustments may be needed in severe impairment. - Avoid use in patients with known severe anaphylactic reactions to biologics. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mepsevii can interact with other medicines; understanding these interactions helps optimize therapy.

Major Interactions (Avoid): - Concomitant use of other enzyme replacement therapies may increase immunogenic risk. - Live attenuated vaccines: efficacy may be reduced; avoid administration during treatment.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR as infusion reactions may affect coagulation. - Immunosuppressants (e.g., azathioprine): observe for altered infection risk. - Antipyretics (e.g., acetaminophen): may mask fever related to infusion reactions.